Arrowhead Pharmaceuticals (ARWR) PT Raised to $4.00 at B. Riley

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective lifted by analysts at B. Riley from $3.00 to $4.00 in a research note issued on Monday. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. B. Riley’s target price would suggest a potential downside of 28.44% from the stock’s previous close.

Several other research analysts have also weighed in on ARWR. Cantor Fitzgerald set a $5.00 target price on Arrowhead Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday. ValuEngine raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. BidaskClub lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Finally, Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective on the stock in a research report on Monday, November 27th. Five research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $4.13.

Arrowhead Pharmaceuticals (ARWR) opened at $5.59 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.63 and a quick ratio of 3.63. The firm has a market capitalization of $485.14, a price-to-earnings ratio of -11.89 and a beta of 2.53. Arrowhead Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $6.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $8.71 million during the quarter, compared to analysts’ expectations of $7.32 million. Arrowhead Pharmaceuticals had a negative return on equity of 40.38% and a negative net margin of 116.17%. analysts predict that Arrowhead Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 1st. The stock was sold at an average price of $3.69, for a total value of $73,800.00. Following the transaction, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ARWR. Virtu KCG Holdings LLC raised its position in Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 53,215 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Arrowhead Pharmaceuticals by 252.2% during the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 31,765 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Arrowhead Pharmaceuticals by 237.3% during the fourth quarter. Wells Fargo & Company MN now owns 69,997 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 49,246 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Arrowhead Pharmaceuticals by 1,177.7% during the fourth quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 66,055 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $305,000. 20.48% of the stock is currently owned by institutional investors.

WARNING: “Arrowhead Pharmaceuticals (ARWR) PT Raised to $4.00 at B. Riley” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/12/arrowhead-pharmaceuticals-arwr-pt-raised-to-4-00-at-b-riley.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply